← Back to Clinical Trials
Recruiting NCT06644352

Right Versus Left Thoracic Surgical Approaches for Siewert II Gastroesophageal Junction Adenocarcinoma

Trial Parameters

Condition Siewert Type II Adenocarcinoma of Esophagogastric Junction
Sponsor Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Study Type INTERVENTIONAL
Phase N/A
Enrollment 236
Sex ALL
Min Age 18 Years
Max Age 80 Years
Start Date 2022-07-01
Completion 2027-07-01
Interventions
different thoracic surgical approaches

Brief Summary

To explore the 5-year overall survival (OS) of right versus left thoracic surgical approaches for patients with locally advanced Siewert II gastroesophageal junction adenocarcinoma treated by neoadjuvant chemotherapy

Eligibility Criteria

Inclusion Criteria: 1. Histologically confirmed gastroesophageal adenocarcinoma; 2. R0 resectable Siewert Ⅱ, cT2-3N0-3M0 (AJCC V8 TNM classification); 3. Have a performance status of 0 or 1 on the ECOG Performance Scale; 4. Age 18-80 years old, both men and women; 5. Estimated survival ≥6 months; 6. Be willing and able to provide written informed consent/assent for the trial; 7. Demonstrate adequate organ function ; 8. Female subject of childbearing potential should have a negative urine or serum pregnancy within 7 days before enrollment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; 9. Have not received systemic or local treatment for esophageal cancer in the past. Exclusion Criteria: 1. Have a history of other malignant tumors in the past or at the same time; 2. Previous upper abdominal surgery (excluding cholecystectomy); 3. Bleeding, perforation and obstruction requiring emergency surgical treatment; 4. Severe heart, lung

Related Trials